MULTIPLE MYELOMA

Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Dr. Jonathan Kaufman explains clinical trial data on the efficacy of dexamethasone with venetoclax for multiple myeloma treatment.

Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Shaji Kumar, MD, describes the mechanism of action of BCL-2 inhibitor venetoclax and clinical trial data on its efficacy in multiple myeloma.

In an interview, Paul G Richardson, MD, discussed the many changes seen in the multiple myeloma space over previous years and what is expected for the future.

Shaji Kumar, MD, discusses the current treatment options and unmet needs for patients with newly diagnosed multiple myeloma.

Paul G. Richardson, MD, discusses the latest regulatory movement in the multiple myeloma space.

During a presentation, Paul G. Richardson, MD, talked about the shift from triplet combination therapies toward quadruplet combinations for the treatment of multiple myeloma.

Adam Cohen, MD, discusses his presentation on updates in BCMA-directed therapies for multiple myeloma, which he gave during the 3rd Summit of the Americas on Immunotherapies for Hematologic Malignancies.

MARCH study in patients with relapsed/refractory multiple myeloma confirms the results of the STORM study and demonstrates positive overall response rates.

Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. An explanation of the role of BCL-2 family proteins in normal cells and in multiple myeloma-affected cells.

Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Jonathan Kaufman, MD, provides an overview of multiple myeloma, including prevalence and risk populations.

The evolving landscape for treating multiple myeloma has seen significant improvement for patients, giving them better options. One of the key regimens added to this landscape is the use of a new quadruplet regimen.

During a live virtual event, Faith E. Davies, MD, discussed treatment options for a patient with multiple myeloma who relapsed after multiple lines of treatment including autologous stem cell transplant.

Treatment options have expanded widely for patients with multiple myeloma over the past several years, resulting in significantly improved outcomes for these patients.

During a Targeted Oncology case-based roundtable event, Sumit Madan, MD, discussed the case of a 55-year-old patient with multiple myeloma who was refractory to multiple lines of therapy.

Ajay Chari, MD, discusses new blood testing options for patients with multiple myeloma.

During a Targeted Oncology case-based roundtable event, Luciano J. Costa, MD, PhD, discussed various treatment regiments for a patient with newly diagnosed multiple myeloma.

Prerna Mewawalla, MD, looks back at a decade of advancements in the multiple myeloma space.

Jesus Berdeja, MD, discusses the safety profile observed with the newly approved chimeric antigen receptor T-cell therapy, ciltacabtagene autoleucel as observed in the phase 1/2 CARTITUDE-1 clincial trial.

Jesus Berdeja, MD, shares factors oncologists in the community should consider when referring patients for chimeric antigen receptorT-cell therapy with the newly approved agent ciltacabtagene autoleucel.

In an interview, Jesus Berdeja, MD, discussed the introduction of ciltacabtagene autoleucel into the treatment landscape for relapsed/refractory multiple myeloma, how it may differ from idecabtagene vicleucel, and the future of CAR T-cell use in the space.

The FDA has granted fast track designation to HPN217, for the treatment of patients with relapsed or refractory multiple myeloma, which is being evaluated in a phase 1/2 clinical trial.

Ciltacabtagene autoleucel had been granted FDA approval for the treatment of select patients with relapsed or refractory multiple myeloma.

During a Targeted Oncology case-based roundtable event, Kenneth Shain, MD, PhD, discussed the case of a patient whose multiple myeloma progressed 1 year after treatment with daratumumab, bortezomib, and dexamethasone.

There are still a lot of things that are ongoing, and the myeloma field is evolving with new treatments, according to Mark Bustoros, MBBCh.

During a live virtual event, Mohamed Baljevic, MD, discussed how to select and sequence combination regimens for multiple myeloma while considering eligibility for autologous stem cell transplant.

During a live virtual event, Natalie Callander, MD, discussed real-world experience with the efficacy of belantamab mafodotin and whether it can be chosen instead of chimeric antigen receptor T-cell therapy.

Jeffrey Zonder, MD, discusses the efficacy results of a first-in-human trial of a bispecific monoclonal antibody in patients with relapsed/refractory multiple myeloma.

During a live virtual event, Muhamed Baljevic, MD, discussed what factors determine whether a patient with stage II multiple myeloma could receive autologous stem cell transplant.

During a live virtual event, Natalie Callander, MD, discussed possible treatment options for a patient who relapsed several years after successful treatment of multiple myeloma with bortezomib, lenalidomide, and dexamethasone.

The anti-CD47 antibody, AO-176, has been granted an FDA orphan drug designation for relapsed or refractory myeloma treatment and is being assessed in a phase 1/2 study.